KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Equivalents (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Cash & Equivalents data on record, last reported at $240.9 million in Q1 2025.

  • For Q1 2025, Cash & Equivalents fell 43.62% year-over-year to $240.9 million; the TTM value through Mar 2025 reached $240.9 million, down 43.62%, while the annual FY2024 figure was $455.5 million, 6.33% up from the prior year.
  • Cash & Equivalents reached $240.9 million in Q1 2025 per SRPT's latest filing, down from $455.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $2.1 billion in Q4 2021 and bottomed at $197.9 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $905.9 million, with a median of $868.6 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 40.81% in 2021, then crashed 63.49% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $2.1 billion in 2021, then plummeted by 54.31% to $966.8 million in 2022, then tumbled by 55.68% to $428.4 million in 2023, then grew by 6.33% to $455.5 million in 2024, then tumbled by 47.12% to $240.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $240.9 million in Q1 2025, $455.5 million in Q4 2024, and $197.9 million in Q3 2024.